PAH抗体;PAH Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of PAH expression in HepG2 cell lysate.    

  
  

**Background of PAH Antibodies**

Phenylalanine hydroxylase (PAH) is a hepatic enzyme critical for metabolizing phenylalanine into tyrosine, a process essential in preventing phenylketonuria (PKU), an autosomal recessive disorder characterized by phenylalanine accumulation. PAH dysfunction due to genetic mutations leads to PKU, necessitating lifelong dietary management. PAH antibodies typically arise in two contexts: autoimmune targeting of PAH or immune responses triggered by enzyme replacement therapies (ERT) or gene therapies.

In autoimmune contexts, anti-PAH antibodies are rare but implicated in immune-mediated liver dysfunction, though their clinical significance remains under investigation. More commonly, PAH antibodies are studied in therapeutic settings. Emerging treatments for PKU, such as pegylated recombinant PAH or gene therapy vectors, may provoke neutralizing antibodies, potentially reducing treatment efficacy. Monitoring anti-PAH antibody levels is thus crucial in clinical trials to assess immunogenicity and optimize dosing strategies.

Research also explores PAH antibodies as diagnostic tools. Immunoassays (e.g., ELISA, Western blot) detect PAH protein expression or mutations, aiding in PKU variant characterization. Current studies focus on modulating immune responses to PAH-targeted therapies, including tolerogenic protocols or engineered PAH variants with reduced immunogenicity. Understanding PAH antibody dynamics bridges translational gaps in PKU management and autoimmune hepatopathies.